Evidence map›Paper›PMID 34631160›Full record

ArticleJournal of transplantation2021

Natural Antibodies and Alloreactive T Cells Long after Kidney Transplantation.

Nicole M van Besouw, Aleixandra Mendoza Rojas, Sarah B See, Ronella de Kuiper, Marjolein Dieterich, Dave L Roelen, Marian C Clahsen-van Groningen, Dennis A Hesselink, Emmanuel Zorn, Carla C Baan

Open access · goldAbstract read
In one paragraph

Article in Journal of transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nicole M van BesouwErasmus MC Transplantation Institute, Department of Internal Medicine-Nephrology & Transplantation and Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0003-4574-9288
Aleixandra Mendoza RojasErasmus MC Transplantation Institute, Department of Internal Medicine-Nephrology & Transplantation and Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands.
Sarah B SeeColumbia Center for Translational Immunology, Columbia University Medical Irving Center, New York, USA.
Ronella de KuiperErasmus MC Transplantation Institute, Department of Internal Medicine-Nephrology & Transplantation and Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands.
Marjolein DieterichErasmus MC Transplantation Institute, Department of Internal Medicine-Nephrology & Transplantation and Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands.
Dave L RoelenDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
Marian C Clahsen-van GroningenErasmus MC Transplantation Institute, Department of Internal Medicine-Nephrology & Transplantation and Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands.
Dennis A HesselinkErasmus MC Transplantation Institute, Department of Internal Medicine-Nephrology & Transplantation and Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands.
Emmanuel ZornColumbia Center for Translational Immunology, Columbia University Medical Irving Center, New York, USA.
Carla C BaanErasmus MC Transplantation Institute, Department of Internal Medicine-Nephrology & Transplantation and Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands.
Erasmus MC · NLColumbia University Irving Medical Center · USLeiden University Medical Center · NL

Funding

Innate B cell immunity and antibody-mediated rejection of human kidney allograftsR01AI123342 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Emmanuel Zorn · 2016 to 2026
$3.3M
NIAID NIH HHS R01 AI123342
6 · The paper itself

Abstract

backgroundThe relationship between circulating effector memory T and B cells long after transplantation and their susceptibility to immunosuppression are unknown. To investigate the impact of antirejection therapy on T cell-B cell coordinated immune responses, we assessed IFN-

methodsPlasma levels of IgG nAbs to malondialdehyde (MDA) were measured in 145 kidney transplant recipients at 5-7 years after transplantation. In 54 of these patients, the number of donor-reactive IFN-

resultsThe number of donor-reactive IFN-

conclusionThe positive correlation found between alloreactive T cells and nAbs in rejectors suggests an intricate role for both components of the immune response in the rejection process. Treatment with intravenous immune globulin impacted nAbs.

Identifiers

PMID34631160
PMCPMC8497134
OpenAlexW3203795025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.